Roche Holding AG (ROG)’s Avastin cancer medicine increases the risk of death and stroke compared with the Lucentis drug when injected into the eye.
Avastin raised the risk of early death by 11 percent and the risk of hemorrhagic stroke by 57 percent compared with Lucentis, Basel, Switzerland-based Novartis AG (NOVN) said today in an e-mailed statement, citing analysis of Medicare data carried out by Johns Hopkins University and presented at a U.S. medical conference. Lucentis was developed by Novartis and Roche’s Genentech unit.
Avastin raised the risk of early death by 11 percent and the risk of hemorrhagic stroke by 57 percent compared with Lucentis, Basel, Switzerland-based Novartis AG (NOVN) said today in an e-mailed statement, citing analysis of Medicare data carried out by Johns Hopkins University and presented at a U.S. medical conference. Lucentis was developed by Novartis and Roche’s Genentech unit.
